Mortality in neurofibromatosis 1: In North West England: An assessment of actuarial survival in a region of the UK since 1989

European Journal of Human Genetics

Volumn 19, Issue 11, 2011, Pages 1187-1191

  Evans, D Gareth R ^a,b   O'Hara, Catherine ^b   Wilding, Anna ^a   Ingham, Sarah L ^a   Howard, Elizabeth ^a   Dawson, John ^a   Moran, Anthony ^b   Scott Kitching, Vilka ^a   Holt, Felicity ^a   Huson, Susan M ^a  

^a ST MARY S HOSPITAL   (United Kingdom)

^b Foundation Trust   (United Kingdom)

Author keywords

autosomal dominant disorder; mortality; neurofibromatosis 1

Indexed keywords

AGED; ARTICLE; CONTROLLED STUDY; FEMALE; GLIOMA; HUMAN; INTELLIGENCE TEST; MAJOR CLINICAL STUDY; MORTALITY; NEUROFIBROMATOSIS; PRIORITY JOURNAL; SURVIVAL; UNITED KINGDOM;

ADOLESCENT; ADULT; AGED; CAUSE OF DEATH; CHILD; CHILD, PRESCHOOL; ENGLAND; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; KAPLAN-MEIER ESTIMATE; LIFE EXPECTANCY; MALE; MIDDLE AGED; NEUROFIBROMATOSIS 1; SEX FACTORS; YOUNG ADULT;

EID: 80054829001     PISSN: 10184813     EISSN: 14765438     Source Type: Journal    
DOI: 10.1038/ejhg.2011.113     Document Type: Article

References (19)

1. Sorensen SA, Mulvihill JJ, Nielsen A: Long term follow up of von Recklinghausen neurofibromatosis: survival and malignant neoplasms. N Engl J Med 1986; 314: 1010-1015 (Pubitemid 16113061)
2. Zöller M, Rembeck B, Akesson HO, Angervall L: Life expectancy, mortality and prognostic factors in neurofibromatosis type 1. A twelve-year follow-up of an epidemiological study in Göteborg, Sweden. Acta Derm Venereol 1995; 75: 136-140
3. Rasmussen SA, Yang Q, Friedman JM: Mortality in neurofibromatosis 1: an analysis using US death certificates. Am J Hum Genet 2001; 68: 1110-1118 (Pubitemid 32424410)
4. Evans DGR, Baser ME, McGaughran J, Sharif S, Donnelly B, Moran A: Malignant peripheral nerve sheath tumours in neurofibromatosis 1. J Med Genet 2002; 39: 311-314 (Pubitemid 34526349)
5. McGaughran JM, Harris DI, Donnai D et al: A clinical study of type 1 neurofibromatosis in North West England. J Med Genet 1999; 36: 192-196
6. Mulvihill JJ, Parry DM, Sherman JL, Pikus A, Kaiser-Kupfer MI, Eldridge R: NIH conference. Neurofibromatosis 1 (Recklinghausen disease) and neurofibromatosis 2 (bilateral acoustic neurofibromatosis). An update. Ann Intern Med 1990; 113: 39-52 (Pubitemid 20196630)
7. Office of National Statistics: Death rates 2008. http://www.statistics. gov.uk/downloads/ theme-health/DR2008/DR-08.pdf
8. Samuelsson B, Samuelsson S: Neurofibromatosis in Gothenburg, Sweden. I. Background, study design and epidemiology. Neurofibromatosis 1989; 2: 6-22 (Pubitemid 19147873)
9. Sharif S, Moran A, Huson SM et al: Women with neurofibromatosis 1 (NF1) are at a moderately increased risk of developing breast cancer and should be considered for early screening. J Med Genet 2007; 44: 481-484 (Pubitemid 47325733)
10. Huson SM, Compston DA, Clark P, Harper PS: A genetic study of von Recklinghausen neurofibromatosis in south east Wales. I. Prevalence, fitness, mutation rate, and effect of parental transmission on severity. J Med Genet 1989; 26: 704-711 (Pubitemid 19270599)
11. Lammert M, Friedman JM, Kluwe L, Mautner VF: Prevalence of neurofibromatosis 1 in German children at elementary school enrolment. Arch Dermatol 2005; 141: 71-74 (Pubitemid 40144442)
12. Evans DG, Howard E, Giblin C et al: Birth incidence and prevalence of tumour prone syndromes: estimates from a UK genetic family register service. Am J Med Genet 2010; 152A: 327-332
13. Imaizumi Y: Mortality of neurofibromatosis in Japan, 1968-1992. J Dermatol 1995; 22: 191-195
14. Walker L, Thompson D, Easton D et al: A prospective study of neurofibromatosis type 1 cancer incidence in the UK. Br J Cancer 2006; 95: 233-238 (Pubitemid 44050923)
15. Evans DGR, Birch JM, Ramsden RT, Moffat D, Baser ME: Malignant transformation and new primary tumours after therapeutic radiation for benign disease: substantial risks in certain tumour-prone syndromes. J Med Genet 2006; 43: 289-294
16. Sharif S, Ferner R, Birch J, Gattamaneni R, Gillespie J, Evans DGR: Second primary tumours in neurofibromatosis 1 (NF1) patients treated for optic glioma: substantial risks post radiotherapy. J Clin Oncol 2006; 24: 2570-2575 (Pubitemid 46630636)
17. Singhal S, Kerr B, Birch J, Lashford L, Evans DGR: Clinical characteristics of symptomatic sporadic and NF1 related optic gliomata: implications for management. Archives Dis Child 2002; 87: 65-70
18. King A, Listernick R, Charrow J, Piersall L, Gutmann DH: Optic pathway gliomas in neurofibromatosis type 1: the effect of presenting symptoms on outcome. Am J Med Genet A 2003; 122A: 95-99 (Pubitemid 37122276)
19. Hartley AL, Birch JM, Kelsey AM, Harris M, Jones PH: Sarcomas in three generations of a family with neurofibromatosis. Cancer Genet Cytogenet 1990; 45: 245-248 (Pubitemid 20129148)